The patented, gene expression test uses a simple, noninvasive method of blood sample collection and can show the low probability of acute cellular rejection in stable heart transplant recipients.
Performed in the XDx CLIA-certified laboratory, AlloMap testing measures the expression levels of 20 genes from a blood sample andthe combined expression of these genes is represented as an AlloMap test score.
AlloMap has been commercially available since 2005 and was cleared by the US Food and Drug Administration in 2008.
XDx president and CEO Pierre Cassigneul said that CTAF’s independent and unbiased recommendations are an important decision-making resource for clinicians and patients, and the CTAF recommendation further validates AlloMap as an important alternative to invasive endomyocardial biopsy in the management of stable heart transplant recipients one that can have a significant impact on patient quality of life.